Reyna Perry
Psychiatric/Mental Health · Toledo, OHNPI 1114621307
Payments from drug & device makers
Across 325 payments — averaging $28.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Axsome Therapeutics, Inc.$985
- Teva Pharmaceuticals USA, Inc.$936
- Otsuka America Pharmaceutical, Inc.$928
- Alkermes, Inc.$802
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$518
- plus $3K from 26 others
What the payments were for
- Food & beverage$9,274100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 54 | $1,670 |
| Axsome Therapeutics, Inc. | 23 | $985 |
| Teva Pharmaceuticals USA, Inc. | 35 | $936 |
| Otsuka America Pharmaceutical, Inc. | 41 | $928 |
| Alkermes, Inc. | 29 | $802 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 31 | $518 |
| Johnson & Johnson | 9 | $472 |
| Neurocrine Biosciences, Inc. | 21 | $437 |
| Corium, LLC | 9 | $345 |
| Lundbeck LLC | 19 | $262 |
| E.r. Squibb & Sons, L.L.C. | 6 | $175 |
| Bioventus LLC | 2 | $155 |
| Braeburn Inc. | 2 | $133 |
| Vanda Pharmaceuticals Inc. | 3 | $126 |
| Eisai Inc. | 1 | $125 |
| Argenx US, Inc. | 1 | $125 |
| Supernus Pharmaceuticals, Inc. | 7 | $117 |
| Stryker | 1 | $116 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $107 |
| Bayer | 1 | $103 |
| Indivior Inc. | 6 | $101 |
| Sanofi-aventis U.S. LLC | 1 | $91 |
| Noven Pharmaceuticals, Inc. | 1 | $81 |
| SK Life Science, Inc. | 1 | $75 |
| Aimmune Therapeutics, Inc. | 1 | $61 |
| Ironshore Pharmaceuticals Inc. | 3 | $59 |
| Sage Therapeutics, LLC | 2 | $49 |
| Tris Pharma Inc | 3 | $43 |
| Luye Pharma (USA) Ltd. | 1 | $30 |
| Noven Therapeutics, LLC | 2 | $28 |
| Bausch Health US, LLC | 1 | $17 |
| Avion Pharmaceuticals | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$959
- Auvelity$584
- ARISTADA$480
- Austedo XR$358
- VRAYLAR$250
- INVEGA SUSTENNA$241
- Azstarys$229
- QULIPTA$125
- UBRELVY$125
- NUEDEXTA$125
- ABILIFY ASIMTUFII$125
- ABILIFY MAINTENA$125
- Leqembi$125
- VYVGART$125
- ARISTADA INITIO$120
- REXULTI$118
- Mavyret$116
- BRIXADI$116
- FLOWTRIEVER CATHETER, S$116
- CT THROMBECTOMY SYSTEM KIT$116
How this compares
$9,286 in reported general payments places this provider in the 95th percentile of 1,808 psychiatric/mental health providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abilify MaintenaAripiprazole | 50 | $139,918 |
| IngrezzaValbenazine Tosylate | 11 | $100,603 |
| VraylarCariprazine Hcl | 57 | $81,337 |
| RexultiBrexpiprazole | 39 | $57,837 |
| LybalviOlanzapine/Samidorphan Malate | 16 | $23,763 |
| TrintellixVortioxetine Hydrobromide | 38 | $18,905 |
| AuvelityDextromethorphan Hbr/Bupropion | 17 | $11,421 |
| Paliperidone ErPaliperidone | 37 | $9,954 |
| Lurasidone Hcl | 25 | $7,793 |
| Aripiprazole | 52 | $6,503 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 41 | $5,257 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 49 | $4,217 |
| Atomoxetine Hcl | 23 | $3,286 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 71 | $3,102 |
| Duloxetine Hcl | 87 | $3,062 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $928 | $197,75589 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $437 | $100,60311 claims |
| AbbVieVraylar | $1,670 | $81,33757 claims |
| Alkermes, Inc.Lybalvi | $802 | $23,76316 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $107 | $18,90538 claims |
| Axsome Therapeutics, Inc.Auvelity | $985 | $11,42117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,808 psychiatric/mental health providers in Ohio.
Other psychiatric/mental health in Toledo
- Christine MillerToledo$12K
- Crystal TravisJackson$333K
- Kristina RoweIronton$253K
- Patricia SparksPortsmouth$210K
- Mary HallWarren$195K
- Kassandra KornbauCanfield$170K
- Terri PopovitzCincinnati$161K
- Steven MatesDayton$121K
- Robert ParsonsYoungstown$119K
- Chriscia BaneChillicothe$115K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.